We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$88M
Cap. Flow
-$194M
Cap. Flow %
-10.24%
Top 10 Hldgs %
47.92%
Holding
151
New
44
Increased
37
Reduced
36
Closed
31
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
1.5 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1 year

Top Buys

Rank Stock Value
1
BKD icon
Brookdale Senior Living
BKD
+$44.7M
2
WELL icon
Welltower
WELL
+$35.8M
3
DOC icon
Healthpeak Properties
DOC
+$33.9M
4
ABVX icon
Abivax
ABVX
+$32.7M
5
OHI icon
Omega Healthcare
OHI
+$26.7M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$48.5M
2
DHR icon
Danaher
DHR
+$42.6M
3
VERA icon
Vera Therapeutics
VERA
+$38.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$31.7M
5
BRKR icon
Bruker
BRKR
+$27.9M

Sector Composition

Rank Sector Weight
1 Healthcare 74.35%
2 Miscellaneous 20.04%
3 Real Estate 5.59%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EVMN icon
101
Evommune Inc
EVMN
$215M
$1.26M 0.07%
+54,680
New +$1.24M
2026 Q1
0 quarters
IMCR icon
102
Immunocore
IMCR
$1.52B
$1.18M 0.06%
+39,238
New +$1.27M
2026 Q1
0 quarters
ASMB icon
103
Assembly Biosciences
ASMB
$419M
$1.13M 0.06%
40,889
-118,787
-74% -$3.39M
2025 Q4
1 quarter
PLRX icon
104
Pliant Therapeutics
PLRX
$60.2M
$1.12M 0.06%
891,425
+49,402
+6% +$62.4K
2025 Q3
2 quarters
SPRY icon
105
ARS Pharmaceuticals
SPRY
$405M
$1.09M 0.06%
136,235
-115,358
-46% -$1.11M
2025 Q3
2 quarters
WHWK icon
106
Whitehawk Therapeutics
WHWK
$173M
$1.06M 0.06%
306,800
+46,541
+18% +$146K
2025 Q4
1 quarter
TYRA icon
107
Tyra Biosciences
TYRA
$1.31B
$1.04M 0.05%
27,055
-251,509
-90% -$8.14M
2025 Q3
2 quarters
PASG icon
108
Passage Bio
PASG
$11.6M
$1.03M 0.05%
131,581
+5,351
+4% +$55.4K
2025 Q4
1 quarter
DHC icon
109
Diversified Healthcare Trust
DHC
$1.84B
$1M 0.05%
+151,283
New +$959K
2026 Q1
0 quarters
INMD icon
110
InMode
INMD
$824M
$927K 0.05%
67,744
+5,806
+9% +$82.8K
2025 Q4
1 quarter
SNDA icon
111
Sonida Senior Living
SNDA
$1.72B
$917K 0.05%
+28,437
New +$951K
2026 Q1
0 quarters
BCYC icon
112
Bicycle Therapeutics
BCYC
$252M
$885K 0.05%
190,715
+11,800
+7% +$67.4K
2025 Q2
3 quarters
EDIT icon
113
Editas Medicine
EDIT
$375M
$719K 0.04%
290,919
– –
2025 Q4
1 quarter
SSII icon
114
SS Innovations International
SSII
$517M
$551K 0.03%
110,157
+34,799
+46% +$167K
2025 Q4
1 quarter
REPL icon
115
CALL
Replimune Group
REPL
$1.11B
$398K 0.02%
+52,000
New +$397K
2026 Q1
0 quarters
RVP icon
116
Retractable Technologies
RVP
$17.6M
$384K 0.02%
580,919
– –
2025 Q3
2 quarters
EHTH icon
117
eHealth
EHTH
$19.4M
$285K 0.02%
220,915
-1,655
-0.7% -$3.83K
2025 Q1
4 quarters
SLQT icon
118
SelectQuote
SLQT
$60.9M
$225K 0.01%
357,661
– –
2025 Q4
1 quarter
AIRS icon
119
AirSculpt Technologies
AIRS
$102M
$210K 0.01%
+74,139
New +$173K
2026 Q1
0 quarters
KPTI icon
120
CALL
Karyopharm Therapeutics
KPTI
$7.96M
$133K 0.01%
+23,800
New +$181K
2026 Q1
0 quarters
ACAD icon
121
Acadia Pharmaceuticals
ACAD
$3.4B
– –
-176,594
Closed -$4.72M –
ASND icon
122
Ascendis Pharma A/S
ASND
$14.9B
– –
-48,241
Closed -$10.3M –
BHVN icon
123
Biohaven
BHVN
$1.73B
– –
-145,431
Closed -$1.64M –
BIIB icon
124
Biogen
BIIB
$34.8B
– –
-77,944
Closed -$13.7M –
BMY icon
125
Bristol-Myers Squibb
BMY
$124B
– –
-235,293
Closed -$12.7M –
3 4
5
6 7

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Eversept Partners held 151 positions worth $1.9B, down 4.4% from $1.98B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Eversept Partners withdrew a net $194M in Q1 2026, closing 31 positions and reducing 36 holdings. Its most notable exit was Danaher, an estimated $42.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Eversept Partners opened a new position in Welltower worth $35.8M.

  • Eversept Partners's largest Q1 2026 buy was Welltower: 180,953 shares worth $35.8M.
  • Eversept Partners added most to Brookdale Senior Living in Q1 2026, an estimated $44.7M increase.
  • Eversept Partners's biggest Q1 2026 reduction was GSK, cutting an estimated $48.5M.
  • Eversept Partners fully exited Danaher in Q1 2026, selling an estimated $42.6M.
  • Eversept Partners's ten largest holdings make up 48% of its $1.9B portfolio in Q1 2026.
  • Eversept Partners opened 44 new positions and closed 31 in Q1 2026.
  • Eversept Partners's portfolio value fell 4.4% quarter-over-quarter to $1.9B.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.